All In Biotech

Drug Trial Radar · NCT02468674

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

A 24 Week Off Drug Extension, Parallel Group, Study Assessing Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind, Placebo Controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia (InvestiGAIT Extension)

Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 22, 2015

Primary completion

Dec 3, 2018

Study completion Dec 3, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.

Conditions

  • Sarcopenia

Interventions

  • bimagrumabDrug

    bimagrumab low dose bimagrumab moderate dose bimagrumab high dose Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.

  • PlaceboDrug

    Placebo Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49Time frame: Week 49
  2. Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49Time frame: Week 49

Locations

30 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Miami Lakes, Florida

  • Novartis Investigative Site

    Gainesville, Georgia

  • Novartis Investigative Site

    Spartanburg, South Carolina

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    St Albans, Victoria, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Copenhagen NV, Denmark

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Ōbu, Aichi-ken, Japan

  • Novartis Investigative Site

    Toyohashi, Aichi-ken, Japan

  • Novartis Investigative Site

    Mizunami, Gifu, Japan

  • Novartis Investigative Site

    Nara, Nara, Japan

  • Novartis Investigative Site

    Kawachi-Nagano, Osaka, Japan

  • Novartis Investigative Site

    Kitaadachigun Inamachi, Saitama, Japan

  • Novartis Investigative Site

    Kitamoto, Saitama, Japan

  • Novartis Investigative Site

    Kiyose, Tokyo, Japan

  • Novartis Investigative Site

    Koto-ku, Tokyo, Japan

  • Novartis Investigative Site

    tabashi City, Tokyo, Japan

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Yaroslavl, Russia

  • Novartis Investigative Site

    Suwon, Gyeonggi-do, South Korea

  • Novartis Investigative Site

    Albacete, Castille-La Mancha, Spain

  • Novartis Investigative Site

    Getafe, Madrid, Spain

  • Novartis Investigative Site

    Geneva, Switzerland

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.